The TNNI3 p.R186Q mutation is responsible for hypertrophic cardiomyopathy via promoting FASN-stimulated abnormal fatty acid metabolism

Abstract

Introduction: The TNNI3 gene encodes the protein of cardiac troponin I (cTnI), which is an inhibitory subunit of sarcomeres. Mutations in this gene account for 3% of hypertrophic cardiomyopathy (HCM) and the molecular mechanism is complex. Recently, lipid metabolism has been revealed to be involved in HCM.

Aim: The purpose of this work is to identify whether the pathological mechanism of the hotspot mutation TNNI3 p.R186Q in HCM is related to abnormal lipid metabolism.

Methods and Results: A knock-in (KI) mouse model carrying the Tnni3 p.R186Q homozygous mutation (Tnni3^R186Q/R186Q) was novelty generated by CRISPR/Cas9 technology and successfully constructed a typical phenotype of cardiac-myopathy. Likewise, neonatal rat cardiomyocytes (NRCMs) transfected with a mutant plasmid with the TNNI3 p.R186Q mutation showed the same phenomenon. In-depth experiments on related functions and molecular mechanisms were conducted, and Tnni3^R186Q/R186Q mice exhibited abnormal fatty acid metabolism, which was induced by the activation of epidermal growth factor receptor (EGFR)-dependent high expression of fatty acid synthase (FASN) in vivo and in vitro. Specifically, the direct binding of EGFR and cTnI was destroyed by TNNI3 p.R186Q mutation, as observed through bioinformatics, Co-IP and GST-pull down analysis.

Conclusion: In the present study, we successfully engineered Tnni3^R186Q/R186Q mice with the typical phenotype of myocardial hypertrophy. We demonstrated that the TNNI3 p.R186Q mutation could induce HCM by the dissociation of EGFR and cTnI, which further led to EGFR-dependent increased expression of FASN and abnormal lipid metabolism.

Keywords

TNNI3 / gene mutation / FASN / hypertrophic cardiomyopathy / abnormal fatty acid metabolism

References

[1] Seidman CE.Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history.Circ Res2011;108:743-50 PMCID:PMC3072749

[2] Ho CY,Ashley EA.Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe).Circulation2018;138:1387-98

[3] Ingles J,Thaxton C.Evaluating the clinical validity of hypertrophic cardiomyopathy genes.Circ Genom Precis Med2019;12:e002460 PMCID:PMC6410971

[4] Mogensen J,Kubo T.Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.J Am Coll Cardiol2004;44:2315-25

[5] Morner S.Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden.J Mol Cell Cardiol2003;35:841-9

[6] Hu J, Xiang Li J, Hong K, Xin Hu J, Brugada P, Shu Cheng X. Hypertrophic cardiomyopathy and planned in vitro fertilization. Genetic testing and clinical evaluation.Herz2012;37:447-52

[7] Carley AN,Lewandowski ED.Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart.Circ Res2014;114:717-29 PMCID:PMC4410983

[8] Glenn DJ,Nishimoto M.A murine model of isolated cardiac steatosis leads to cardiomyopathy.Hypertension2011;57:216-22 PMCID:PMC3322545

[9] Krishnan J,Windak R.Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy.Cell Metab2009;9:512-24

[10] Menendez JA.Fatty acid synthase (FASN) as a therapeutic target in breast cancer.Expert Opin Ther Targets2017;21:1001-16

[11] Che L,Cigliano A.Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.Cell Cycle2017;16:499-507 PMCID:PMC5384589

[12] Reinecke H,Bartosek T.Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts.Circulation1999;100:193-202

[13] Zhou Q,Liu X.FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3.J Mol Cell Cardiol2018;116:115-24

[14] Peng X,Shen Y.FAT10 protects cardiac myocytes against apoptosis.J Mol Cell Cardiol2013;59:1-10 PMCID:PMC3646899

[15] Thupari JN,Ronnett GV.C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity.Proc Natl Acad Sci USA2002;99:9498-502 PMCID:PMC123169

[16] Hurtado-de-Mendoza D,Pozios I.Diffuse interstitial fibrosis assessed by cardiac magnetic resonance is associated with dispersion of ventricular repolarization in patients with hypertrophic cardiomyopathy.J Arrhythm2017;33:201-7 PMCID:PMC5459419

[17] Willott RH,Chang AN,Pinto JR.Mutations in troponin that cause HCM, DCM AND RCM: what can we learn about thin filament function?.J Mol Cell Cardiol2010;48:882-92

[18] Ghashghaee N, Li KL, Solaro RJ, Dong WJ. Role of the C-terminus mobile domain of cardiac troponin I in the regulation of thin filament activation in skinned papillary muscle strips.Arch Biochem Biophys2018;648:27-35 PMCID:PMC5977403

[19] Klip A,Chiu TT.Signal transduction meets vesicle traffic: the software and hardware of GLUT4 translocation.Am J Physiol Cell Physiol2014;306:C879-86

[20] Legchenko E,Borchert P.PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.Sci Transl Med2018;10:eaao0303

[21] Saini-Chohan HK,Vaz FM,Hatch GM.Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: thematic review series: genetics of human lipid diseases.J Lipid Res2012;53:4-27 PMCID:PMC3243479

[22] Wang ZV,Hill JA.Heart failure and loss of metabolic control.J Cardiovasc Pharmacol2014;63:302-13 PMCID:PMC3980079

[23] He L,Long Q.Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity.Circulation2012;126:1705-16 PMCID:PMC3484985

[24] Kienesberger PC,Sung MM.Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction.Mol Cell Biol2012;32:740-50 PMCID:PMC3272983

[25] Chung H,Cho SM.Differential contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of hypertrophic cardiomyopathy.Mitochondrion2020;53:48-56

[26] Baker ZN,Boulet A.The mitochondrial metallochaperone SCO1 maintains CTR1 at the plasma membrane to preserve copper homeostasis in the murine heart.Hum Mol Genet2017;26:4617-28 PMCID:PMC5886179

[27] Ricchiuti V.RNA expression of cardiac troponin T isoforms in diseased human skeletal muscle.Clin Chem1999;45:2129-35

[28] Nguyen S,Dewey S,Gomes AV.Amino acid changes at arginine 204 of troponin I result in increased calcium sensitivity of force development.Front Physiol2016;7:520 PMCID:PMC5108889

[29] Wee P.Epidermal growth factor receptor cell proliferation signaling pathways.Cancers2017;9:52 PMCID:PMC5447962

[30] Cabarcas SM,Farrar WL.Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.Curr Mol Med2010;10:744-55 PMCID:PMC3448443

[31] Menendez JA,Ortega FJ.Fatty acid synthase: association with insulin resistance, type 2 diabetes, and cancer.Clin Chem2009;55:425-38

[32] Jung MY,Hernandez DM.Fatty acid synthase is required for profibrotic TGF-β signaling.FASEB J2018;32:3803-15 PMCID:PMC5998981

[33] Zhang J,Zhao X.EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer.Mol Cancer2017;16:127 PMCID:PMC5518108

[34] Polonio-Alcalá E,Torres-Oteros D.Fatty acid synthase inhibitor G28 shows anticancer activity in EGFR tyrosine kinase inhibitor resistant lung adenocarcinoma models.Cancers2020;12:1283 PMCID:PMC7281741

[35] Ali A,Teo JT.Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.EMBO Mol Med2018;10 PMCID:PMC5840543

[36] Ommen SR,Burke MA.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.J Am Coll Cardiol2020;76:e159-240

[37] Sherrid MV,Winson G.Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.Circ Heart Fail2013;6:694-702

[38] Peng K,Qian Y.Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II.J Cell Mol Med2016;20:482-94 PMCID:PMC4759478

[39] Liang D,Hu J.EGFR inhibition protects cardiac damage and remodeling through attenuating oxidative stress in STZ-induced diabetic mouse model.J Mol Cell Cardiol2015;82:63-74